Gossamer Bio, Inc.
GOSS
$2.46
-$0.07-2.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -58.02% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -58.02% | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -58.02% | -- | -- | -- | -- |
| SG&A Expenses | -3.69% | -7.04% | -6.04% | -15.24% | -17.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.48% | 6.91% | 0.51% | -11.06% | -19.23% |
| Operating Income | -109.86% | 67.35% | 65.51% | 66.77% | 66.08% |
| Income Before Tax | -86.20% | 70.83% | 69.06% | 63.54% | 63.05% |
| Income Tax Expenses | -179.86% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -71.60% | 70.31% | 68.56% | 61.77% | 60.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -71.60% | 70.31% | 68.56% | 61.77% | 60.90% |
| EBIT | -109.86% | 67.35% | 65.51% | 66.77% | 66.08% |
| EBITDA | -113.03% | 67.43% | 65.67% | 67.00% | 66.36% |
| EPS Basic | -94.68% | 64.68% | 71.42% | 81.97% | 82.36% |
| Normalized Basic EPS | -144.94% | 52.98% | 62.97% | 83.22% | 83.59% |
| EPS Diluted | -94.74% | 64.78% | 71.50% | 81.99% | 82.38% |
| Normalized Diluted EPS | -136.99% | 51.81% | 62.09% | 82.54% | 83.04% |
| Average Basic Shares Outstanding | 4.23% | 22.52% | 48.68% | 89.27% | 131.59% |
| Average Diluted Shares Outstanding | 2.77% | 24.18% | 50.71% | 91.85% | 134.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |